Hostname: page-component-8448b6f56d-42gr6 Total loading time: 0 Render date: 2024-04-25T02:32:31.713Z Has data issue: false hasContentIssue false
  • English
  • Français

Lack of effect of electroconvulsive therapy on CSF peptide concentrations in schizophrenic patients

Published online by Cambridge University Press:  13 June 2014

Stephen J Cooper ,
C F Johnston  and
David J King
Stephen J Cooper
Affiliation:
Dept. of Mental Health, The Queens University of Belfast, The Whitla Medical Building, 97 Lisburn Road, Belfast BT 9 7BL
C F Johnston
Affiliation:
Wellcome Research Laboratory, Dept. of Medicine, Mulhouse Building, QUB
David J King
Affiliation:
Dept. of Therapeutics and Pharmacology, The Whitla Medical Building, QUB
Get access Rights & Permissions [Opens in a new window]

Abstract

The effects of a series of 6 ECT treatments were observed on the CSF concentrations of neurotensin and substance-P in eight patients suffering from schizophrenia. Four patients were previously drug free. No significant effects of ECT were observed.

Keywords

SchizophreniaECTneurotensinSubstance-P
Type
Clinical & Brief Reports
Information
Irish Journal of Psychological Medicine , Volume 8 , Issue 2 , September 1991 , pp. 132 - 134
Copyright
Copyright © Cambridge University Press 1991

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Buch, SJ, Deshmukh, PP, Burks, TF, Yamamura, HI. A survey of substance P, somatostatin, and neurotensin levels in ageing in the rat and human central nervous system. Neurobiol Ageing 1981; 2: 257–264.CrossRefGoogle Scholar
2.Cooper, PE, Fernstrom, MH, Rorstad, OP, Leeman, SE, Martin, JB. The regional distribution of somatostatin, substance P and neurotensin in human brain. Brain Res 1981; 218: 219–232.CrossRefGoogle ScholarPubMed
3.Nicholl, RA, Alger, BE, Jahr, CE. Peptides as putative excitatory neurotransmitters: carnosine, enkephalin, substance P and TRH. Proceedings of the Royal Society of London. Series B: Biological Sciences 1980; 210: 133–149.Google Scholar
4.Sawada, S, Takada, S, Yamamoto, C. Electrical activity recorded on thin sections of the bed nucleus of the stria terminalis and the effects of neurotensin. Brain Res 1980; 180: 578–581.CrossRefGoogle Scholar
5.Nemeroff, CB, Hernandez, D, Luttinger, D, Kalivas, PW, Prange, AJ. Interactions of neurotensin with brain dopamine systems. Ann NY Acad Sci 1982; 400: 330–344.CrossRefGoogle ScholarPubMed
6.Widerlov, E, Kilts, C, Mailman, RB, Nemeroff, CB, McCowen, TJ, Prange, AJ, Breese, JR. Increase in dopamine metabolites in rat brain by neurotensin. J Pharmacol Exp Ther 1982; 223: 1–6.Google ScholarPubMed
7.Nemeroff, CB. Neurotensin: perchance an endogenous neuroleptic. Biol Psychiatry 1980; 15: 283–302.Google ScholarPubMed
8.Ghatei, MA, Bloom, SR, Langevin, H, McGregor, GP, Lee, YC, Adrian, TE, O'Shaughnessy, DJ, Blank, MA, Uttenthal, LO. Regional distribution of bombesin and seven other regulatory peptides in the human brain. Brain Res 1984; 293: 101–108.CrossRefGoogle ScholarPubMed
9.Hong, JS, Yang, H-YT, Costa, E. Substance P content of substantia nigra after chronic treatment with antischizophrenia drugs. Neuropharmacology 1978; 17: 83–85.CrossRefGoogle Scholar
10.Owen, F, Cross, AJ, Crow, TJ, Longden, A, Poulter, M, Riley, GJ. Increased dopamine receptor sensitivity in schizophrenia. Lancet 1978; ii: 223–226.CrossRefGoogle Scholar
11.Johnstone, EC, Crow, TJ, Frith, CD, Carney, MWP, Price, JS. Mechanism of the antipsychotic effect in the treatment of acute schizophrenia. Lancet 1978; i: 848–851.CrossRefGoogle Scholar
12.Cooper, SJ, Leahey, W, Green, DF, King, DJ. The effect of electroconvulsive therapy on CSF amine metabolites in schizophrenic patients. Br J Psychiatry 1988; 152: 59–63.CrossRefGoogle ScholarPubMed
13.Bissette, G, Levant, B, Nemeroff, CB. Neurotensin involvement in the action of antipsychotic drugs and the pathogenesis of schizophrenia. Clin Neuropharmacol 1990; 13 (suppl 2): 599–600.Google Scholar
14.Feighner, JB, Robins, E, Guze, SB, Woodruff, RA, Winokur, G, Munoz, R. Diagnostic criteria for use in psychiatric research Arch Gen Psychiatry 1972; 26: 57–63.CrossRefGoogle Scholar
15.Krawiecka, M, Goldberg, D, Vaughn, MA. A standardised psychiatric assessment scale for rating chronic psychotic patients. Acta Psychiatr Scand 1977; 55: 299–308.CrossRefGoogle ScholarPubMed
16.Shaw, C, Buchanan, KD. Intact neurotensin (NT) in human plasma: response to oral feeding. Regulatory Peptides 1983; 7: 145–153.CrossRefGoogle ScholarPubMed
17.Abdullah, LL, Buchanan, KD. A comparison of substance P (SP) antisera produced by different immunization procedures. In: Skrabanek, P, Powell, D, editors. Substance P; Dublin 1983. Dublin: Boole Press, 1983; 32–33.Google Scholar
18.Widerlov, E, Lindstrom, LH, Besev, G, Manberg, PJ, Nemeroff, CB, Breese, GR, Kizer, JS, Prange, AJ. Subnormal CSF levels of neurotensin in a sub-group of schizophrenic patients: normalization after neuroleptic treatment. Am J Psychiatry 1982; 139: 1122–1126.Google Scholar
19.Roberts, GW, Ferrier, IN, Lee, Y, Crow, TJ, Johnstone, EC, Owens, DGC, Bacarese-Hamilton, AJ, McGregor, G, O'Shaughnessey, D, Polak, JM, Bloom, SR. Peptides, the limbic lobe and schizophrenia. Brain Res 1983; 288: 199–211.CrossRefGoogle ScholarPubMed
20.Kleinman, JE, Hong, J, Iadarola, M, Govoni, S, Gillin, CJ. Neuropeptides in human brain – postmortem studies. Progress in Neuro-Psychopharmacol and Biol Psychiat 1985; 9: 91–95.CrossRefGoogle ScholarPubMed
21.Carruthers, B, Dawbarn, D, de Quidt, M, Emson, PC, Hunter, J, Reynolds, GP. Changes in neuropeptide content of anygdala in schizophrenia. Br J Pharmacol 1984; 81: 190P.Google Scholar
22.Manberg, PJ, Nemeroff, CB, Bissette, G, Widerlov, E, Youngblood, WW, Kizer, JS, Prange, AJ. Neuropeptides in CSF and post-mortem brain tissue of normal controls, schizophrenics and Huntington's choreics. Progress in Neuro-Psychopharmacol and Biol Psychiat 1985; 9: 97–108.CrossRefGoogle ScholarPubMed
23.Post, RM, Goodwin, FK. Time dependent effects of phenothiazines on dopamine turnover in psychiatric patients. Science 1975; 190: 488–489.CrossRefGoogle ScholarPubMed
24.Kee, DB, Wood, JH. Physiological neuroendocrinology of peptides, steroids and other hormones in cerebrospinal fluid. Prog Neuropsychopharmacol 1985; 9: 55–27.CrossRefGoogle ScholarPubMed